Detection of Aspirin Resistance by PFA-100: Prevalence and Aspirin Compliance in Patients with Chronic Stable Angina

ABSTRACT

Most acute coronary syndromes result from a platelet-rich occlusion of the coronary arteries. Antiplatelet drugs are of proven efficacy in preventing myocardial infarction, unstable angina, and stroke. However, not all patients on aspirin (ASA) benefit. We studied the phenomenon of aspirin resistance with a simple and reliable platelet function analyzer-the PFA-100. Studying 31 patients with unstable angina and 105 controls, we found aspirin resistance in 42% of patients, most of whom were shown to be compliant utilizing concomitant salicylate levels.

KEYWORDS

Platelets - platelet activation - PFA-100 - nitrates - aspirin resistance - salicylate levels

REFERENCES

• 1 Kannel W B. Bishop Lecture: Contribution of the Framingham Study to preventive cardiology.  J Am Coll Cardiol. 1990;  15 206-211
• 2 Heller R F, Chinn S, Pedoe H D, Rose G. How well can we predict coronary heart disease? Findings in the United Kingdom Heart Disease Prevention Project.  BMJ (Clin Res Ed). 1984;  288 1409-1411
• 3 Cairns J A, Gent M, Singer J et al.. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multi-center trial.  N Engl J Med. 1985;  313 1369-1375
• 4 Lewis Jr H D, Davis J W, Archibald D G et al.. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.  N Engl J Med. 1983;  309 396-403
• 5 Antithrombotic Trialists' Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for the prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324 71-86
• 6 Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn P F. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men.  Circulation. 1991;  84 613-617
• 7 Tofler G H, Brezinski D, Schafer A I et al.. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death.  N Engl J Med. 1987;  316 1514-1518
• 8 Vilen L, Johansson S, Kutti J, Cronberg S, Vedin A, Wilhelmsson C. ADP-induced platelet aggregation in young female survivors of acute myocardial infarction and their female controls.  Acta Med Scand. 1985;  217 9-13
• 9 [No authors listed] . Secondary prevention of vascular disease by prolonged antiplatelet treatment.  Antiplatelet Trialists Collaboration.  Br Med J (Clin Res Ed). 1988;  296 320-331
• 10 Buchanan M R, Brister S J. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically.  Can J Cardiol. 1995;  11 221-227
• 11 Helgason C M, Bolin K M, Hoff J A et al.. Development of aspirin resistance in persons with previous ischemic stroke.  Stroke. 1994;  25 2331-2336
• 12 Cahill M, Mistry R, Chapman C, Barnett D B. Effects of age, sex, and oral contraceptives on the platelet membrane fibrinogen binding site (glycoprotein IIb/IIIa).  Br J Clin Pharmacol. 1992;  33 11-15
• 13 Cahill M R, Macey M G, Newland A C. Fixation with formaldehyde induces expression of activation dependent platelet membrane glycoproteins, P-selectin (CD62) and GP53 (CD63).  Br J Haematol. 1993;  84 527-529
• 14 Harrison P. Progress in the assessment of platelet function.  Br J Haematol. 2000;  111 733-744
• 15 Kundu S K, Heilmann E J, Sio R et al.. Characterization of an in vitro platelet function analyzer, PFA-100™.  Semin Thromb Hemost. 1995;  21 106-112
• 16 Kundu S K, Heilmann E J, Sio R, Garcia C, Davidson R M, Ostgaard R A. Description of an in vitro platelet function function analyzer-PFA-100.  Semin Thromb Hemost. 1995;  21 (suppl 2) 106-112
• 17 Rodgers R P, Levin J. A critical reappraisal of the bleeding time.  Semin Thromb Hemost. 1990;  16 1-20
• 18 Elwood P C, Renaud S, Sharp D S, Beswick A D, O'Brien J R, Yarnell J W. Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study.  Circulation. 1991;  83 38-44
• 19 Zahavi J, Kakkar V V. β-thromboglobulin-a specific marker of in vivo platelet release reaction.  Thromb Haemost. 1980;  44 23-29
• 20 Marshall P W, Williams A J, Dixon R M et al.. A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers.  Br J Clin Pharmacol. 1997;  44 151-155
• 21 Cattaneo M, Federici A B, Lecchi A et al.. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease.  Thromb Haemost. 1999;  82 35-39
• 22 Fressinaud E, Veyradier A, Truchaud F et al.. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases.  Blood. 1998;  91 1325-1331
• 23 Mammen E F, Comp P C, Gosselin R et al.. PFA-100^™ system: a new method for assessment of platelet dysfunction.  Semin Thromb Hemost. 1998;  24 195-202
• 24 Bock M, de Haan J, Beck K-H et al.. Standardization of the PFA-100 platelet function test in 105 mmol/L buffered citrate: effect of gender, smoking, and oral contraceptives.  Br J Haematol. 1999;  106 898-904
• 25 Heilmann E J, Kundu S K, Sio R, Garcia C, Gomez R, Christie D J. Comparison of four commercial citrate blood collection systems for platelet function analysis by the PFA-100 system.  Thromb Res. 1997;  87 159-164
• 26 Cahill M R, Macey M G, Dawson J R, Newland A C. Prevention of restenosis after angioplasty.  Lancet. 1994;  343 1361
• 27 Fitzgerald D J, Roy L, Catella F, Fitzgerald G A. Platelet activation in unstable coronary disease.  N Engl J Med. 1986;  315 983-989
• 28 Hirsh P D, Hillis L D, Campbell W B, Firth B G, Willerson J T. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease.  N Engl J Med. 1981;  304 685-691
• 29 De Boer A C, Turpie A GG, Butt R W, Johnston R V, Genton E. Platelet release and thromboxane synthesis in symptomatic coronary artery disease.  Circulation. 1982;  66 327-333
• 30 Gormsen J, Dalsgaard-Neilsen J, Agerskov-Andersen L. ADP-induced platelet aggregation in vitro in patients with ischaemic heart disease and peripheral thrombo-atherosclerosis.  Acta Med Scand. 1977;  201 509-513
• 31 Gum P A, Kottke-Marchant K, Poggio E D et al.. Profile and prevalence of aspirin resistance in patients with cardiovascular disease.  Am J Cardiol. 2001;  88 230-235
• 32 McKee S A, Sane D C, Deliargyris E N. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms and clinical significance.  Thromb Haemost. 2002;  88 711-715
• 33 von Pape K, Aland E, Bohner J. Platelet function analysis with PFA-100 in patients medicated with acetylsalicylic acid strongly depends on concentration of sodium citrate used for anticoagulation of blood samples.  Thromb Res. 2000;  98 295-299
• 34 Fitzgerald G A. Parsing an enigma: the pharmacodynamics of aspirin resistance.  Lancet. 2003;  361 542-543
• 35 Macchi L, Christiaens L, Brabant S et al.. Resistance in vitro to low-dose aspirin is associated with platelet PLA1 (GP IIIa) polymorphism but not with c807T (GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms.  J Am Coll Cardiol. 2003;  42 1115-1119
• 36 MacDonald T M, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin.  Lancet. 2003;  361 573-574
• 37 Marcus A J, Broekman M J, Pinsky D J. COX inhibitors and thromboregulation.  N Engl J Med. 2002;  347 1025-1026